Eid, Karine http://orcid.org/0000-0002-5158-7636
Torkildsen, Øivind
Aarseth, Jan
Celius, Elisabeth G.
Cortese, Marianna
Holmøy, Trygve
Kapali, Akash
Myhr, Kjell-Morten
Torkildsen, Cecilie F.
Wergeland, Stig
Gilhus, Nils Erik
Bjørk, Marte-Helene
Funding for this research was provided by:
Helse Vest Regionalt Helseføretak (F-12503)
Norges Forskningsråd (288164)
University of Bergen
Article History
Received: 28 April 2022
Revised: 17 June 2022
Accepted: 20 June 2022
First Online: 3 July 2022
Declarations
:
: K. Eid has received unrestricted research grant and speaker honoraria from Novartis. Ø. Torkildsen has received speaker honoraria from and served on scientific advisory boards for Biogen, Sanofi-Aventis, Merck and Novartis. J. Aarseth has no competing interests to declare that are relevant to the content of this article. E. G. Celius has received honoraria for lecturing and advice from Biogen, Bristol Meyers Squibb, Janssen, Novartis, Merck, Roche and Sanofi, and her department has received grants from Novartis and Sanofi. M. Cortese has no competing interests to declare that are relevant to the content of this article. T. Holmøy has received speaker honoraria from Biogen, Merck, Novartis, Roche, Bristol Myers Squibb, and Sanofi and has participated in clinical trials organized by Biogen, Merck, and Roche. A. Kapali has no competing interests to declare that are relevant to the content of this article. K.M. Myhr has received unrestricted research grants to his institution; scientific advisory board and speaker honoraria from Biogen, Merck, Novartis, Roche, and Sanofi and has participated in clinical trials organized by Biogen, Merck, Novartis, Roche, and Sanofi. C.F. Torkildsen has served on scientific advisory board for Astra Zeneca. S. Wergeland has received honoraria from Biogen, Novartis, Janssen, and Sanofi. N.E. Gilhus has received honoraria from UCB, Ra, Argenx, Roche, Merck, Immunovant, Alexion. M.H. Bjørk has received personal honoraria for lecturing from Teva, Lilly, Eisai, and Novartis, consultancy honoraria from Jazz pharmaceuticals, Lundbeck and Novartis, unrestricted research support from Novartis and institutional contract research fees from Sanofi.
: The establishment of MoBa was based on a license from the Norwegian Data Protection Agency and approval from the Regional Committees for Medical and Health Research Ethics (REK). The MoBa cohort is regulated by the Norwegian Health Registry Act. Ethics approval for the current study was obtained from REK (reference 2016/906).
: Written informed consent for use of information in research and for data linkage was acquired during enrollment in MoBa and the MS Registry.